Biocon Prepares For Life After Pfizer
This article was originally published in PharmAsia News
Following the dissolution of its global biosimilars deal with Pfizer, Biocon Chairman Kiran Mazumdar-Shaw speaks with PharmAsia News about the path ahead.
You may also be interested in...
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.